» Articles » PMID: 16082560

Loss of P16INK4A Expression is Associated with Allelic Imbalance/loss of Heterozygosity of Chromosome 9p21 in Microdissected Synovial Sarcomas

Overview
Journal Virchows Arch
Date 2005 Aug 6
PMID 16082560
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Deletions of the short arm of chromosome 9 have been observed in many tumours and cell lines. This chromosomal region is frequently targeted during malignant transformation because it contains at least two known tumour suppressor genes: p16(INK4) and p15(INK4B). p16(INK4A) acts as a negative cell cycle regulator by inhibiting G1 cyclin-dependent kinases that phosphorylate the retinoblastoma protein and therefore block the progression of the cell cycle from G1 to S phase. The role of p16(INK4A) in the development of synovial sarcoma has not been comprehensively investigated. Ten samples of synovial sarcomas were examined for allelic imbalance/loss of heterozygosity (AI/LOH) of the 9p region and p16 protein expression. DNA was isolated from microdissected sections of normal and tumour cells, amplified by polymerase chain reaction and analysed for AI/LOH by using six microsatellite markers that map to the 9p region. Immunohistochemistry for p16 expression was done. AI/LOH with at least one microsatellite marker on 9p21 was detected in six of ten samples. The most frequent allelic deletions were observed within the coding sequence of p16(INK4A). Loss of p16 immunoreactivity was detected in eight samples, six of which showed evidence of alterations at 9p21 region. These findings suggest a possible role of loss of p16(INK4A) in the development of synovial sarcoma.

Citing Articles

Whole-exon sequencing insights into pancreatic synovial sarcoma: a case report.

Mao Q, Pan H, Liu B, Jin M, Fu G, Shao H Gland Surg. 2021; 10(5):1812-1818.

PMID: 34164326 PMC: 8184378. DOI: 10.21037/gs-20-680.


Performance of the UroVysion FISH assay for the diagnosis of malignant effusions using two cutoff strategies.

Rosolen D, Faria D, Faria C, Antonangelo L Cancer Med. 2018; 7(5):1967-1977.

PMID: 29577646 PMC: 5943432. DOI: 10.1002/cam4.1442.


Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients.

Vlenterie M, Hillebrandt-Roeffen M, Schaars E, Flucke U, Fleuren E, Navis A Ann Surg Oncol. 2016; 23(9):2745-52.

PMID: 27334220 PMC: 4972869. DOI: 10.1245/s10434-016-5341-x.

References
1.
Cohen J, Geradts J . Loss of RB and MTS1/CDKN2 (p16) expression in human sarcomas. Hum Pathol. 1997; 28(8):893-8. DOI: 10.1016/s0046-8177(97)90003-4. View

2.
Sabah M, Cummins R, Leader M, Kay E . Loss of heterozygosity of chromosome 9p and loss of p16INK4A expression are associated with malignant gastrointestinal stromal tumors. Mod Pathol. 2004; 17(11):1364-71. DOI: 10.1038/modpathol.3800199. View

3.
Schneider-Stock R, RADIG K, Roessner A . Loss of heterozygosity on chromosome 9q21 (p16 gene) uncommon in soft-tissue sarcomas. Mol Carcinog. 1997; 18(2):63-5. DOI: 10.1002/(sici)1098-2744(199702)18:2<63::aid-mc1>3.0.co;2-r. View

4.
Dos Santos N, de Bruijn D, Van Kessel A . Molecular mechanisms underlying human synovial sarcoma development. Genes Chromosomes Cancer. 2000; 30(1):1-14. DOI: 10.1002/1098-2264(2000)9999:9999<::aid-gcc1056>3.0.co;2-g. View

5.
Hannon G, Beach D . p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature. 1994; 371(6494):257-61. DOI: 10.1038/371257a0. View